{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 122 of 129', 'Appendix 5: Guidance for anaphylaxis diagnosis (24)', 'The National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy and', 'Anaphylaxis Network Guidance for Anaphylaxis Diagnosis (FAAN) define anaphylaxis as a', 'serious allergic reaction that is rapid in onset and may cause death. They recognise', '3 categories of anaphylaxis, with criteria designated to capture from 80% of cases', '(category 1) to >95% of all cases of anaphylaxis (for all 3 categories).', 'Clinical criteria for diagnosing anaphylaxis', 'Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:', '1) Acute onset of an illness (minutes to several hours) with involvement of the skin,', 'mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-', 'tongue-uvula)', 'AND AT LEAST ONE OF THE FOLLOWING:', 'Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor,', 'reduced peak expiratory flow [PEF], hypoxemia)', 'Reduced blood pressure (BP) or associated symptoms of end-organ', 'dysfunction (e.g., hypotonia [collapse], syncope, incontinence)', '2) Two or more of the following that occur rapidly after exposure to a likely allergen for', 'that patient (minutes to several hours):', 'Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush,', 'swollen lips-tongue-uvula)', 'Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor,', 'reduced PEF, hypoxemia)', 'Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope,', 'incontinence)', 'Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)', '3) Reduced BP after exposure to known allergen for that patient (minutes to several', 'hours):', 'Infants and children: low systolic BP (age specific) or greater than 30%', 'decrease in systolic BP', 'Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from', \"that person's baseline\", 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 123 of 129', 'Appendix 6: Contact list', 'Contact list of LEO, protocol authors, vendors, and trial committees', \"Contact details for the clinical project manager, national lead CRA (NLCRA), and sponsor's\", 'medical expert are provided to the trial sites as a separate contact list.', 'Sponsor', \"LEO Pharma A/S (referred to as 'LEO' or 'the sponsor' in this clinical trial protocol) is the\", 'sponsor of the clinical trial:', 'LEO Pharma A/S', 'Industriparken 55', 'DK-2750 Ballerup', 'Denmark', 'International coordinating investigator', 'Associate Professor Jonathan Silverberg, MD, PhD, MPH, Departments of Dermatology,', 'Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School', 'of Medicine, United States', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 124 of 129', 'CROs/vendors', 'Service', 'Name and address', 'Data management', 'Quanticate Ltd.', 'Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire SG5 1LH', 'United Kingdom', 'ePRO', 'CRF Health Management Ltd.', '3rd Floor, Brook House, 229-243 Shepherds Bush Road, Hammersmith,', 'London W6 7AN', 'United Kingdom', 'ECG', 'Cardiabase S.A.S.', 'Villa Alsacienne, 78 Avenue du XXe Corps, 54000 Nancy', 'France', 'Central laboratory', 'ACM Global Central Laboratory', '23 Hospital Fields Road, York YO10 4DZ', 'United Kingdom', 'Bioanalysis of PK and', 'Covance Laboratories Ltd.', 'ADA samples', 'Otley Road, Harrogate, North Yorkshire HG3 IPY', 'United Kingdom', 'IWRS', 'Quanticate Ltd.', 'Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire SG5 1LH', 'United Kingdom', 'CMO', 'Almac Clinical Services Ltd.', 'Almac House, 20 Seagoe Industrial Estate, Craigavon BT63 5QD', 'United Kingdom', 'Emergency unblinding', 'C3i, Inc', 'CRO', '25 Lindsley Drive, Morristown, NJ 07960', 'United States of America', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}